{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106"}]}],"title":"Grade II-IV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}],"title":"Grade III-IV"}],"denoms":[{"counts":[{"groupId":"OG000","value":"212"}],"units":"Participants"}],"description":"Determine the incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) at day 100 after UCBT. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria following Przepiorka et al, 1995, Consensus Clinical Stage and Grade of Acute GVHD.\n\nPatients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.","groups":[{"description":"Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.","id":"OG000","title":"Unrelated UCBT for Blood Cancers"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 100","title":"Number of Participants With Acute Graft-Versus-Host Disease","type":"SECONDARY","unitOfMeasure":"Participants"}